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A B S T R A C T  
Introduction : Rice bran ara bi noxy lan com pound (RBAC) is a nu traceu ti cal for en hanc ing a de pleted im mune 
sys tem dur ing and af ter can cer treat ment. This pi lot fea si bil ity trial aims to eval u ate the ef fects of RBAC on 
can cer pa tients' qual ity of life dur ing ac tive treat ment, com pared to placebo, us ing a val i dated ques tion naire. 
Other out come mea sures in clude changes in in flam ma tory and nu tri tional sta tus, cy tokine pro file, and gut mi - 
cro biota. 
Methods/ Design : The study will re cruit 50 par tic i pants from a re gional can cer cen ter in Aus tralia. Pa tients aged 
18 – 70, di ag nosed with solid or gan can cers stage II and above, and cur rently un der go ing ac tive sys temic ther a - 
pies, are el i gi ble. Ran dom al lo ca tion of par tic i pants into two groups is strat i fied based on metasta tic sta tus and 
treat ment type. The dosage is ei ther 3 g/ day of RBAC or placebo in iden ti cal pack ag ing. The par tic i pants, 
study co or di na tor, and treat ing on col o gists are blinded to the in ter ven tions. Data col lec tions are at base line 
and at four fol low - up ses sions, which are six weeks apart (24 weeks). Sta tis ti cal analy sis will in volve a pro - 
tected p - value with mul ti ple de pen dent val ues and an a lyzed by ANOVA with re peated mea sures on the oc ca - 
sion of test ing and with both a full Bon fer roni or Sidak cor rec tions ap plied to pro tect against Type I er rors. 
Any ob served sig nif i cance war rants fur ther analy sis with pair wise com par isons. Analy sis of co vari ance will 
also be per formed to as sess any in flu ence of the de mo graphic data, can cer di ag no sis, as well as changes in 
phys i cal ac tiv ity, di etary habits, and com ple men tary med i cine us age. Com par isons of gut mi cro biota will be 
based on the analy sis of the fe cal mi cro biome us ing 16S ri bo so mal ri bonu cleic acid am pli con se quenc ing. The 
pro posed re search time line is from Oc to ber 2018 to May 2022. 
Trial registration : ANZCTR. Reg No: AC TRN12619000562178p. 
1 . Introduction 
The health - related qual ity of life (QoL) of can cer pa tients in cludes 
the pa tients' sub jec tive per cep tions of symp toms, phys i cal, emo tional, 
so cial, and cog ni tive func tions, as well as side ef fects of treat ment [ 1 ]. 
Achiev ing ben e fits in terms of QoL has be come in creas ingly im por tant 
in can cer treat ment, with the tra di tional end point of sur vival deemed 
in suf fi cient as the only treat ment out come [ 1 ]. 
Im mune dys func tion lead ing to in flam ma tion is the un der ly ing 
mech a nism that af fects the pa tient phys i cally and emo tion ally, which 
also in di rectly im pacts so cial func tion ing [ 2 ]. In flam ma tion is a hall - 
mark of can cer as it is as so ci ated with the mi croen vi ron ment of al - 
most all tu mor sites [ 3 – 5 ]. Per sis tent, lo cal ized in flam ma tion can lead 
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to the leak ing of pro - inflammatory cy tokines into cir cu la tion and ini ti - 
ates a sys temic in flam ma tory cas cade [ 6 , 7 ]. There is a con sis tent re la - 
tion ship be tween in creas ing sys temic in flam ma tion and wors en ing of 
all QoL pa ra me ters, such as global health, role, phys i cal and so cial 
func tion ing, and fa tigue, pain, ap petite symp toms [ 3 , 8 ]. In creased in - 
flam ma tion in the cen tral ner vous sys tem also trig gers be hav ioral co - 
mor bidi ties, in clud ing de pres sion, anx i ety, fa tigue, cog ni tive dis tur - 
bances, and neu ro pathic pain, which af fect QoL [ 9 ]. 
Rice bran ara bi noxy lan com pound (RBAC) can po ten tially im prove 
the QoL of can cer pa tients by mod u lat ing the im mune and in flam ma - 
tory re sponses. The par tially ab sorbed RBAC di rectly ex erts im - 
munomod u lat ing ef fects, which in clude up reg u lat ing nat ural killer 
(NK) cell ac tiv ity, aug ment ing phago cytic cel lu lar func tions, mod u lat - 
ing cy tokines pro duc tion, and pro mot ing T and B lym pho cyte pro lif er - 
a tion, in ad di tion to act ing as a nat ural ad ju vant for den dritic cells 
(DCs) [ 10 – 13 ]. The re main ing com po nents that are re sis tant to di ges - 
tion serve as pre bi otics to the gut mi cro biota. The gut mi cro biota can 
in di rectly in duce anti - inflammatory and im munomod u lat ing ef fects in 
the host [ 14 ], and af fect be hav ioral changes via the gut - brain axis 
[ 15 ]. The com bined ef fects up reg u late the im mune cells into the anti - 
tumor phe no types and bal ance the se cre tion of pro - and anti - 
inflammatory cy tokines, lead ing to the re duc tion in sys tem atic in flam - 
ma tion. QoL en hance ments such as sub jec tive im prove ments in sleep, 
ap petite, di ges tion, phys i cal ac tiv ity, and de crease in anx i ety and pain 
as well as re duced ad verse ef fects dur ing can cer ther apy, have been 
re ported in sev eral RBAC case stud ies [ 16 – 23 ]. Sup ple men ta tion with 
RBAC (250 mg/ d) for three months also sig nif i cantly en hanced the 
QoL scores (mea sured with SF - 12v2 ques tion naire) of healthy old 
adults (n = 60) in a ran dom ized con trolled trial (RCT) [ 24 ]. 
Clin i cal re search on the ef fect of RBAC on can cer pa tients' QoL is 
still in its early stage. Only a small num ber of clin i cal tri als [ 25 – 28 ] 
are avail able in the lit er a ture (see Table 1 ). These tri als suf fer from 
sev eral lim i ta tions, in clud ing in ad e quate study de sign with un clear 
risks of bias as well as the use of non - validated QoL mea sure ments. 
Fur ther more, placebo treat ment is well known to pos i tively af fect 
QoL, es pe cially in im proved con trol of symp toms such as pain, ap - 
petite, and fa tigue but rarely with ac tual tu mor re sponse [ 29 , 30 ]. 
None of the ex ist ing tri als at tempted to rule out the im pact of placebo 
in the ob served QoL im prove ment. As such, there is a lack of well - 
designed RCTs that in ves ti gate the ef fect of RBAC on the QoL of can - 
cer pa tients. Specif i cally, there is no clin i cal trial that at tempts to as - 
sess the ef fect of RBAC on can cer pa tients' QoL com pared to placebo 
us ing a val i dated QoL ques tion naire along side mea sures of cy tokines 
and gut mi cro biome re sponses. 
2 . Methods/ Design 
2. 1 . Objectives 
The RBAC - QoL study (Pro to col No. H19244, ver sion 2.2.1, re lease 
Feb ru ary 24, 2020) is a 24 - week ran dom ized placebo - controlled pi lot 
fea si bil ity trial with the study co or di na tor, pa tients, and the on col o - 
gists blinded to the in ter ven tion. The pri mary ob jec tive is to de ter - 
mine the po ten tial ef fect of RBAC com pared to placebo on the QoL of 
can cer pa tients un der go ing ac tive treat ment, based on the Eu ro pean 
Or gan i sa tion for the Re search and Treat ment of Can cer (EORTC) core 
30 - item QoL ques tion naire (QLQ - C30 ver sion 3.0). The ef fect size es ti - 
mate on the QLQ - C30 scores will in form the plan ning of a larger trial 
for fur ther hy poth e sis test ing. 
A sec ondary ob jec tive is to de ter mine changes in the nu tri tional 
and in flam ma tory sta tus of the body as ad di tional out come mea sures 
as so ci ated with the changes in the pa tients' QoL. As ex ploratory mea - 
sures, this study also aims to as sess the im munomod u lat ing ef fects of 
RBAC based on changes in cy tokines pro file, as well as changes in the 
di ver sity and com po si tion of gut mi cro biota as po ten tial un der lin ing 
mech a nisms of RBAC sup ple men ta tion. 
2. 2 . Study setting and recruitment 
The study site is a re gional can cer cen ter in the Cen tral West ern of 
New South Wales, Aus tralia. Re cruit ment will tar get pa tients start ing 
ac tive treat ment in the cen ter, in clud ing those with newly di ag nosed 
or re cur rent can cer. El i gi ble pa tients will be re ferred to the trial by 
their treat ing on col o gists. A study co or di na tor, trained in Good Clin i - 
cal Prac tice, will dis cuss the trial with po ten tial par tic i pants based on 
the in for ma tion pro vided on the Pa tient In for ma tion Sheet and Con - 
sent Form (Sup ple men tary S1). Pa tients will be given at least 24 h for 
con sid er a tion of the pro ject and un der take in formed dis cus sions with 
their pri mary - care doc tors and with fam ily mem bers. The study co or - 
di na tor will fol low up with po ten tial par tic i pants to pro vide clar i fi ca - 
tion and sub se quently ob tain writ ten con sent from will ing par tic i pants 
in the pres ence of the prin ci pal in ves ti ga tor on site. 
Table 1 
Sum mary of clin i cal tri als eval u at ing the ef fects of RBAC on the QoL of can cer pa tients. 
Study Patients Design Interventions Outcomes Limitations 
Takahara 
& Sano 
[ 26 ] 
Progressive and metastasized 
cancer patients. N = 205 





3 g/day RBAC with CAT versus 
CAT only. 
RBAC group achieved a higher survival rate 
and better appetite than the control group. 
Non - validated QoL questionnaire 
for appetite, pain, malaise, and 
nausea only; Unclear effect of 




[ 25 ] 
Breast cancer patients. 






3 g/day RBAC 1 week before & 
1 week after each 
chemotherapy cycle versus 
chemotherapy only. 6 cycles of 
chemotherapy. 
RBAC group experienced a significant 
reduction in tiredness, increased appetite; no 
anti - emetic needs; and less hair fall compared 
to the control group. 
Non - validated QoL questionnaire; 
No placebo - control; Lack of 
detailed statistical analysis. 
Hajto et 
al. 
[ 27 ] 
Advanced (II - IV) stages 
cancer patients of various 
malignancies. N = 35. 
Non - randomized 
trial. Duration: 
6 months. 
12 – 45 mg/kg of RBAC plus 
0.5 – 1.0 ng/kg mistletoe lectin 
twice a week. Conventional 
oncologic therapy. 
Improvement of physical activity and decrease 
of side effects during conventional 
oncotherapy. 
Non - randomized study; RBAC was 
not applied as a monotherapy. 
Petrovics 
et al. 
[ 28 ] 
Cancer patients (with 
different malignancies) with 
chronic fatigue syndrome. 






3 g/day of RBAC and 
Oncothermia for 24 weeks with 
chemo - or radiotherapy as 
routine care versus routine care 
only. 
RBAC group showed changes in body pH 
levels to be less acidic. The average fatigue 
scale was significantly reduced in the RBAC 
group compared to no change in the control 
group. 
RBAC was not applied as a 
monotherapy; the QLQ - C30 
questionnaire was used but results 
not reported. 
Ab bre vi a tions: RBAC, rice bran ara bi noxy lan com pound; CAT, com ple men tary and al ter na tive ther a pies; QoL, qual ity of life; QLQ - C30, qual ity of life ques tion - 
naire – core 30 ques tions. 
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2. 3 . Sample size 
As there is no pre vi ous study of RBAC sup ple ment on the QoL of 
can cer pa tients based on the QLQ - C30 ques tion naire, there is no ef fect 
size data for per form ing a pri ori analy sis for the re quired sam ple size. 
We have se lected the sam ple size of the pre sent study based on the 
fol low ing con sid er a tions: 
1. The guidelines for sample size calculations for QLQ - C30 scores by 
Cocks et al. [ 31 ] indicate that a standardized effect size of 0. 35 
for the Global QoL score is considered a small effect that is likely 
to be clinically relevant. Analysis with F - tests (ANOVA with two 
groups and five repeated measures) using a priori parameters with 
an alpha of 0. 05, power 0. 8, and an effect size of 0. 35 resulted in 
a total sample size of 42. 
2. For a standardized effect size of 0. 25, Cocks and Torgeson [ 32 ] 
also recommended a sample size of 42 for the main trial of 
continuous outcome measures with a power of 0. 8 based on one - 
sided confidence interval calculation. 
3. Whitehead et al. [ 33 ] recommended the sample size per 
intervention arm to be 25 in a pilot trial for any main trial 
designed with 90% power, two - sided 5% significance, and small 
standardized effect size (0. 2). 
Hence, a to tal sam ple size be tween 42 and 50 is deemed rea son - 
able. This study will have a sam ple size of 50, with 25 in each group 
to cater for any po ten tial dropout. This num ber also rep re sents a prac - 
ti cal choice since the study site is a small cen ter with a lim ited num - 
ber of pa tients. Re cruit ment will be on - going un til the de sired sam ple 
size is reached. 
2. 4 . Eligibility criteria 
In clu sion cri te ria : Adult pa tients aged 18 – 70 years old at the time 
of pro vid ing in formed con sent; Di ag nosed with any solid or gan can cer 
(in clud ing colon, breast, melanoma, lung, pan cre atic, blad der, and 
prostate) of stage II and above; Cur rently un der go ing ac tive treat ment 
for can cer; Re ceived an ex pla na tion of the pur pose and meth ods of 
the study; Pro vided writ ten con sent prior to the start of the trial; Ad e - 
quately main tained ma jor or gan func tion (bone mar row, liver, and 
kid neys) with lab o ra tory pa ra me ters as shown in Table 2 . 
Ex clu sion cri te ria : Ex ist ing men tal health con di tions that may im - 
pede the abil ity to pro vide con sent; In abil ity to com plete QoL ques - 
tion naire with min i mal as sis tance; Preg nant, lac tat ing, or plan to get 
Table 2 
Screen ing pa ra me ters for el i gi ble pa tients. 
# Parameter Required level 
A. Bone Marrow Function 
i. Absolute neutrophil count 
(ANC) 
> 1.5 × 10 9 /L 
ii. Platelet count ≥100 × 10 9 /L 
iii. Haemoglobin ≥10.0 g/dl 
B. Hepatic Function 
i. Aspartate transaminase 
(AST) 
≤3x ULN 
ii. Alanine transaminase (ALT) ≤3x ULN 
iii. Bilirubin ≤1.5x ULN (<2 x ULN if hyperbilirubinemia is 
due to Gilbert's syndrome) 
C . Renal Function 
i. Estimated glomerular 
filtration rate (eGFR) 
≥45 ml/min using the Cockcroft - Gault 
Ab bre vi a tions: dl – decil itre; g – gram; L – Litre; ml – mil li liter; min – minute; 
ULN – Up per Limit of Nor mal. 
preg nant dur ing the pe riod of the study; Ac tive or prior doc u mented 
au toim mune or in flam ma tory dis or ders within the last five years, ex - 
cept for vi tiligo or alope cia, sta ble hy pothy roidism on hor mone re - 
place ment, and any chronic skin con di tion that does not re quire sys - 
temic ther apy. Pa tients with chronic but sta ble con di tions, in clud ing 
di a betes, hy per ten sion, and chronic ob struc tive pul monary dis ease, 
will not be ex cluded. 
2. 5 . Interventions 
The in ter ven tions are ei ther RBAC or placebo pow der for 24 
weeks. As shown in Table 3 , each RBAC sa chet con tains 1 g of the ac - 
tive in gre di ent with 1 g of ex cip i ents (To tal = 2 g). The placebo pow - 
der con tains 1.26 g of in ert corn starch and 0.74 g of other ex cip i ents 
(To tal = 2 g). The placebo has a slight dif fer ence in ex cip i ent con - 
tents to achieve ac cept able melt in the mouth, as well as a neg li gi ble 
amount of caramel, which is for bind ing and color match ing. The 
placebo is sim i lar in color, odor, and taste com pared to the ac tive 
com pound. The plas tic sa chets that con tain both RBAC and placebo 
pow der are also iden ti cal in ap pear ance, mak ing them in dis tin guish - 
able by the par tic i pants. 
The par tic i pants will take two sa chets in the morn ing and one sa - 
chet in the evening as a di etary sup ple ment dur ing or af ter meals for a 
to tal daily dosage of 3 g of RBAC. The par tic i pants are to thor oughly 
mix the con tents into half a glass (ap prox i mately 125 ml) of wa ter 
and drink it right away. Should the par tic i pants need to fast be fore 
their treat ment, they should also stop tak ing the sup ple ment un til 
they re sume eat ing. 
To en sure ad her ence, the study co or di na tor will re peat edly pro - 
vide in struc tions for tak ing sup ple ment sa chets, in clud ing tim ing, 
stor age, and what to do in the event of a missed dose dur ing ini tial 
dis pens ing and every sub se quent visit. The par tic i pants are to re turn 
un used sa chets at each fol low - up visit to be counted and recorded for 
com pli ance as sess ment. 
Par tic i pants will con tinue their ac tive can cer treat ment and med - 
ica tions as in structed by their treat ing on col o gists. How ever, all con - 
comi tant med ica tions used dur ing the study will be recorded and up - 
dated at base line and dur ing each visit. 
2. 6 . Assignment of interventions 
To en sure both groups have the same size, the man u fac turer will 
sup ply a to tal of 50 in ter ven tion pack ages equally di vided be tween 
RBAC and placebo (25:25). The pack ages will be la beled se quen tially 
from 1 to 50 by in ter mix ing RBAC and placebo. Each sa chet within 
will also be marked ac cord ing to the num ber as signed to the con tain - 
ing pack age. A mas ter list that records the ac tual con tents will be kept 
in a se cure folder with ac cess lim ited to the re search team only af ter 
the ex per i ment is com plete. 
As stages of can cer di ag no sis at base line and the types of treat - 
ment un der gone are con found ing vari ables that can af fect QoL, par tic - 
i pants are al lo cated into the two groups us ing strat i fied ran dom iza - 
Table 3 
The in gre di ents of an ac tive or placebo in ter ven tion sa chet (net weight in 
mil ligram, mg). 
Ingredient Active Placebo 
Microcrystalline Cellulose 500 500 
Modified Starch 260 1260 
Dextrin 200 200 
Tricalcium Phosphate 40 40 
Rice bran arabinoxylan compound 1000 – 
Caramel – Δ 
Total 2000 2000 
Δ – An in fin i tes i mal amount of caramel is added for col or ing and as a binder. 
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tion, based on metasta tic sta tus (yes or no) and treat ment type 
(chemother apy or im munother apy). Upon re cruit ment, the par tic i pant 
will be as signed a unique iden ti fier (Range: 1 – 50), gen er ated with a 
com puter pro gram, to re ceive the sup ple ment pack age of the cor re - 
spond ing num ber. The study co or di na tor who re cruits the par tic i pants 
has no means to in flu ence the al lo ca tion and no knowl edge of the po - 
ten tial al lo ca tion out come. The par tic i pant, the treat ing on col o gist, 
and the study co or di na tor (data col lec tor) in ter act ing with the par tic i - 
pants dur ing each visit for as sess ment will be blinded to study in ter - 
ven tion. 
To con ceal al lo ca tion but al low for emer gency code - breaking, the 
in for ma tion of the ac tual in ter ven tion con tents is kept in opaque en - 
velopes that are num bered and sealed in ad vance. A code break is 
done through open ing the cor re spond ing sealed en ve lope and should 
oc cur only in ex cep tional and highly un likely cir cum stances. For in - 
stance, when knowl edge of the ac tual con tent is es sen tial in the opin - 
ion of the treat ing on col o gist for man age ment of an ad verse event, po - 
ten tially due to RBAC. All code breaks (with rea son) will be recorded. 
2. 7 . Outcome measures 
The QLQ - C30 has both multi - item scales and sin gle - item mea sures. 
These in clude five func tional scales (phys i cal, role, emo tional, cog ni - 
tive, and so cial), three symp tom scales (fa tigue, nau sea & vom it ing, 
pain), a global health sta tus/ QoL scale, and six sin gle items (dys p nea, 
in som nia, ap petite loss, con sti pa tion, di ar rhea, fi nan cial dif fi cul ties). 
Scor ing of QoL fol lows the EORTC/ QLQ - C30 man ual [ 34 ], with each 
item/ scale mapped to a lin ear trans for ma tion of 0 – 100. The mean 
score of each item/ scale on the QLQ - C30 will be cal cu lated for each 
group at each study time point for the mean dif fer ence be tween - group 
com par i son. This pi lot study aims to de ter mine which of these scales/ 
items are the most ap pro pri ate pri mary out come mea sures that best 
re flect any po ten tial ef fect of RBAC com pared to placebo on the QoL 
of can cer pa tients. 
Sec ondary out come mea sures are the as sess ment of the nu tri tional 
and in flam ma tory sta tus of the pa tients, which in clude body com po si - 
tion (body weight, mus cle mass, body fat per cent age), body mass in - 
dex, the neu trophil to lym pho cyte ra tio (NLR), and the in flam ma tory - 
nutritional in dex (INI = the ra tio of C - Reactive Pro tein [CRP] and al - 
bu min). 
Ex ploratory out come mea sures are cy tokines pro file, as shown in 
Table 4 , which will be eval u ated sep a rately to as sess the po ten tial im - 
munomod u lat ing ef fects of RBAC. Ad di tion ally, stool sam ples will be 
col lected through out the trial for the analy sis of changes in the gut 
mi cro biota of the par tic i pants who pro vide ad di tional con sent. The 
study will as sess com par isons of the mi cro biota di ver sity (al pha di ver - 
sity) and com po si tion of dif fer ent gut bac te ria groups (beta di ver sity) 
be tween the two dif fer ent groups of pa tients by study ing the fe cal mi - 
cro biome based on 16S ri bo so mal ri bonu cleic acid (rRNA) gene se - 
quenc ing. 
2. 8 . Data collection, management, and analysis 
Fig. 1 shows the time line of par tic i pa tion. Par tic i pants will com - 
plete the QLQ - C30 ques tion naire at base line and on four vis its, each 
at six weeks apart. The body com po si tion of the par tic i pants will be 
mea sured us ing a body com po si tion mon i tor (Tanita In ner Scan BC - 
587) based on the Bio elec tric Im ped ance Analy sis tech nol ogy. 
Diet, ex er cise, and con cur rent use of com ple men tary ther a pies are 
known con found ing vari ables that may af fect can cer pa tients' QoL 
out comes. To en sure the changes of QoL are the ef fect as so ci ated with 
the in ter ven tion and not due to changes in lifestyle be hav iors, data on 
the par tic i pants' diet, phys i cal ac tiv i ties, and use of com ple men tary 
ther a pies dur ing the trial will also be col lected us ing an on line food 
fre quency ques tion naire (The Aus tralian Eat ing Sur vey® FFQ), the In - 
Table 4 
Hu man cy tokine/ chemokine ar ray 42 - plex. 
# Cytokine/Chemokine Name 
1 EGF Epidermal growth factor 
2 Eotaxin - 1 Eosinophil chemotactic protein (CCL11) 
3 FGF - 2 Basic fibroblast growth factor 
4 Flt - 3L Fms - related tyrosine kinase 3 ligand 
5 Fractalkine Chemokine (C - X3 - C motif) ligand 
6 G - CSF Granulocyte colony - stimulating factor 
7 GM - CSF Granulocyte - Macrophage Colony - Stimulating Factor 
8 GROα Chemokine (C - X - C motif) ligand 1 
9 IFNα2 Interferon alpha - 2 
10 IFNγ Interferon - gamma 
11 IL - 10 Interleukin 10 (cytokine synthesis inhibitory factor) 
12 IL - 12P40 Interleukin - 12 subunit p40 
13 IL - 12P70 Interleukin - 12 subunit p70 
14 IL - 13 Interleukin - 13 
15 IL - 15 Interleukin - 15 
16 IL - 17A Interleukin - 17A 
17 IL - 18 Interleukin 18 
18 IL - 1α Interleukin 1 alpha 
19 IL - 1β Interleukin 1 beta 
20 IL - 1RA Interleukin 1 receptor antagonist 
21 IL - 2 Interleukin 2 
22 IL - 3 Interleukin 3 
23 IL - 4 Interleukin 4 
24 IL - 5 Interleukin 5 
25 IL - 6 Interleukin 6 
26 IL - 7 Interleukin 7 
27 IL - 8 Interleukin 8 
28 IL - 9 Interleukin 9 
29 IP - 10 Interferon gamma - induced protein 10 (CXCL10) 
30 MCP - 1 Monocyte Chemoattractant Protein - 1 
31 MCP - 3 Monocyte chemotactic protein 3 
32 MDC Macrophage - derived chemokine 
33 MIP - 1α Macrophage Inflammatory Proteins 1α (CCL3) 
34 MIP - 1β Macrophage Inflammatory Proteins 1β (CCL4) 
35 PDGF - AA Platelet - Derived Growth Factor - AA 
36 PDGF - BB Platelet - Derived Growth Factor - BB 
37 RANTES Regulated on activation, normal T cell expressed and 
secreted (CCL5) 
38 sCD40L Soluble CD40 ligand 
39 TGF - α Transforming growth factor - alpha 
40 TNF - α Tumour necrosis factor - alpha 
41 TNF - β Tumour necrosis factor - beta 
42 VEGF - A Vascular endothelial growth factor - A 
ter na tional Phys i cal Ac tiv ity Ques tion naire, and a Use of Com ple men - 
tary and Al ter na tive Med i cine Ques tion naire specif i cally de vel oped 
for this study (See sup ple men tary S2), re spec tively. How ever, in or der 
not to over bur den the par tic i pants, com ple tion of these ad di tional 
ques tion naires is op tional. Par tic i pants can de cide whether to com - 
plete these ques tion naires at the time of pro vid ing con sent. 
Blood sam ples will be col lected by a lo cal patho log i cal lab o ra tory 
within four days be fore or three days af ter every visit. All blood tests 
re quired, ex cept the cy tokine pro file, will be tested lo cally with the 
re sults trans mit ted to the can cer cen ter elec tron i cally for rou tine clin i - 
cal use. The study co or di na tor will record all re quired blood test re - 
sults in a data col lec tion form. Ad di tional blood sam ples will be cen - 
trifuged into serum and stored at −80 °C. The serum sam ples will be 
sent to a rep utable com mer cial com pany for the pro fil ing of cy tokines 
in batches. 
Stool sam ple col lec tion, stor age, and analy sis will fol low a stan - 
dard ized pro to col to en sure re li able gut mi cro biome analy sis [ 35 ]. 
Since fe cal test ing is not part of the stan dard of care in can cer treat - 
ment, the col lec tion of stool sam ples is also an op tional study com po - 
nent. The par tic i pants can choose not to pro vide their stool sam ples at 
the time of con sent. A con sented par tic i pant will be in structed to take 
a swab of his/ her stool sam ple us ing a fit - for - purpose spec i men col lec - 
tion kit (Mi croba Re search Par tic i pant Sam pling Kit) be tween one to 
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Fig. 1 . RBAC - QoL clin i cal trial par tic i pa tion time line. 
three days be fore the next visit to the patho log i cal lab o ra tory. The 
par tic i pant is to sub mit the col lected sam ple to the patho log i cal lab o - 
ra tory. The col lected sam ple is stored at −80 °C un til dis patch ing to a 
mi cro bi ol ogy lab o ra tory for ex trac tion of de oxyri bonu cleic acids 
(DNA) us ing the QI Aamp® Pow erFe cal® Pro DNA Kit. Se quenc ing of 
the V4 re gion of the 16S rRNA am pli fied from ex tracted DNA will be 
con ducted us ing the Il lu mina MiSeq plat form. 
The tim ing of the study visit will be syn chro nized with the par tic i - 
pants' treat ment cy cles to pro mote re ten tion and com plete fol low - up. 
A sched uled visit that is within one week be fore or af ter ( ±7 days) 
the six - week in ter val is per mit ted. The trial will fol low the par tic i - 
pants for the en tire study pe riod. How ever, par tic i pants can with draw 
con sent from the study for any rea son at any time. Fur ther more, the 
prin ci pal in ves ti ga tor may re move par tic i pants from the trial ei ther 
for safety rea sons or if they are un will ing or un able to com ply with 
re quired study pro ce dures. Any rea son for dropout will be recorded. 
The con fi den tial ity of par tic i pants will be main tained through out 
the study. Data will be cap tured di rectly at the can cer cen ter with all 
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case forms (See sup ple men tary S3 – Case Re port Forms) and study 
doc u ments kept in locked cab i nets. No in di vid ual par tic i pant can be 
iden ti fied in any study re ports and pub li ca tions. All com pleted forms 
will be elec tron i cally scanned and up loaded to se cure cloud stor age 
(Cloud Stor). Other elec tronic study data will be stored at the re search 
data stor age of the spon sor. Only the re search team can ac cess, man - 
age, and an a lyze the data. All data stor age and man age ment fol lows 
the Re search Data Man age ment Guide lines of the spon sor and will be 
re tained for 15 years af ter the com ple tion and pub li ca tion of re sults. 
De - identified study data may be shared with the fun ders or other in - 
sti tu tions for re search use with ex plicit agree ments. All sharable data 
will not con tain any per sonal in for ma tion. 
Sta tis ti cal analy sis of the col lected re sults will be con ducted us ing 
R ver sion 3.4.0 or later. The RBAC group will be com pared against 
the placebo group for analy sis. A pro tected p - value with mul ti ple de - 
pen dent val ues will be an a lyzed by ANOVA with re peated mea sures 
on the oc ca sion of test ing with a full Bon fer roni, or Sidak, ad justed p - 
value de pend ing on the cor re la tion among the de pen dent vari ables. 
Pair wise com par isons will be per formed where sig nif i cance is ob - 
served. Analy sis of co vari ance will also be per formed to as sess any in - 
flu ence of the de mo graphic data (age, gen der, eth nic ity) and can cer 
di ag no sis (pri mary can cer type, dis ease stage, re cur rence, etc.), 
changes in phys i cal ac tiv ity, changes in di etary habits, as well as 
changes in com ple men tary med i cine us age level on the out come vari - 
ables with ob served be tween and/ or within - group sig nif i cance. Ad di - 
tional analy sis in sub groups or based on pro to col non - adherence will 
be per formed if ap plic a ble. A de tailed sta tis ti cal analy sis plan will be 
pre pared be fore the start of data analy sis. 
Data analy sis of the 16S rRNA se quences will be an a lyzed with QI - 
IME2 (Quan ti ta tive In sights into Mi cro bial Ecol ogy 2 soft ware) 
pipeline [ 36 ]. Al pha di ver sity will be cal cu lated us ing the rich ness of 
ASVs (Am pli con Se quence Vari ants), Chao1 in dex, Shan non in dex, 
and Faith's phy lo ge netic di ver sity [ 37 , 38 ] and dis played with R soft - 
ware. Beta di ver sity will be mea sured us ing both weighted and un - 
weighted UniFrac dis tance met rics [ 39 ]. Pat terns in di ver sity as a re - 
sponse to the ap pli ca tion of RBAC will be vi su al ized with PCoA (Prin - 
ci pal Co or di nate Analy sis) [ 40 ] with the sta tis ti cal sig nif i cance of 
group ings val i dated with an ANOSIM (Analy sis Of SIM i lar ity) test 
[ 41 ] in the con text of other po ten tially in ter act ing vari ables in the 
dataset. Dif fer en tially abun dant mi cro bial taxa that dis tin guish be - 
tween treat ments will be iden ti fied us ing AN COM (Analy sis of Com - 
po si tion of Mi cro bio mes) [ 42 ] and fur ther vi su al ized with the 
WGCNA (Weighted Cor re la tion Net work Analy sis) pack age, gg plot2 
pack ages and stat pack age in R soft ware with p < 0.05 taken as sta - 
tis ti cal sig nif i cance. 
A fi nal study re port pro vid ing full de tails of the study meth ods and 
re sults will be com piled as a doc toral the sis by the lead au thor for ex - 
am i na tion. Sum mary of the study re sults will be sub mit ted for pub li - 
ca tion in an in ter na tional peer - reviewed jour nal with the at tri bu tion 
of au thor ship based on sub stan tial con tri bu tions. The study par tic i - 
pants will also re ceive a copy of the sum mary of re sults. This study 
pro to col con forms with the Stan dard Pro to col Items Rec om men da - 
tions for In ter na tional Tri als (See Sup ple men tary S4 – SPIRIT 2013 
Check list). 
2. 9 . Safety monitoring 
A pi lot fea si bil ity trial with a small sam ple size does not war rant 
the for ma tion of an in de pen dent data safety mon i tor ing board and ex - 
ter nal au dit ing. Hence, the Trial Ex ec u tive Com mit tee (TEC) con sist - 
ing of four re search team mem bers (SCP, PM, RZ, and SLO) who over - 
see all as pects of the trial man age ment, will con duct safety data mon i - 
tor ing. All ad verse events oc cur ring dur ing the study will be tracked 
us ing the Com mon Ter mi nol ogy Cri te ria for Ad verse Events ver sion 
5.0 grad ing. Safety data will be re viewed by the TEC every four weeks 
in ac cor dance with the Na tional Health and Med ical Re search Coun - 
cil's Guid ance on 'Safety mon i tor ing and re port ing in clin i cal tri als in - 
volv ing ther a peu tic goods' [ 43 ]. A par tic i pant will only dis con tinue 
the in ter ven tion un der the ad vice of the treat ing on col o gist, should 
any in ter ven tion - related ad verse event of Grade 3 (se vere or med - 
ically sig nif i cant but not im me di ately life - threatening) or above oc cur. 
The par tic i pant will be re tained in the study, when ever pos si ble, for 
fol low - up data col lec tion to min i mize miss ing data even af ter dis con - 
tin u ing the as signed in ter ven tion. Should a par tic i pant suf fer from 
com pli ca tions as a re sult of the study, med ical treat ment will be ren - 
dered free of charge un der Medicare in any Aus tralian pub lic hos pi tal 
as a pub lic pa tient. The TEC will have the abil ity to ter mi nate the 
study for safety rea sons. 
2. 10 . Research ethics and approval 
This study con forms to the Aus tralian Na tional State ment on Eth i - 
cal Con duct in Hu man Re search [ 44 ]. The eth i cal as pects of this re - 
search pro ject have been ap proved by the Hu man Re search Ethics 
Com mit tee (HREC) of Con cord Repa tri a tion Gen eral Hos pi tal, Syd ney 
Lo cal Health Dis trict (Ap pli ca tion No. 2019/ ETH00489), and the 
spon sor ing uni ver si ty's HREC (Pro to col No. H19244). We also re - 
ceived a site - specific au tho riza tion from the Greater West ern NSW Lo - 
cal Health Dis trict Re search Ethics and Gov er nance Of fice (Ap pli ca - 
tion No. 2019/ STE10547). As this clin i cal trial in volves the use of an 
‘un ap proved’ ther a peu tic good (namely, RBAC) and its placebo, a no - 
ti fi ca tion is sub mit ted to the Ther a peu tic Goods Ad min is tra tion of 
Aus tralia be fore com mence ment. This study is reg is tered on the Aus - 
tralian New Zealand Clin i cal Tri als Reg istry (Reg is tra tion No. AC - 
TRN12619000562178p). All the gov ern ing bod ies will be no ti fied in 
case of any ma te r ial changes to the study pro to col. 
3 . Discussion 
The RBAC used in this study is a wa ter - soluble, low mol e c u lar 
weight (30 – 100 kDa), mod i fied ara bi noxy lan with xy lose in its main 
chain and an ara bi nose poly mer in its side chain [ 45 ]. This com pound 
is mar keted in Aus tralia un der the brand name Ri braxx, whereas it is 
bet ter known in ter na tion ally as Bio bran/ MGN - 3, Lentin Plus (Asia), or 
BRM4 (United States). It is a safe and non - toxic sub stance, as demon - 
strated in a se ries of an i mal stud ies [ 46 ]. Fur ther more, a sys tem atic 
re view of RBAC for can cer pa tients found no ad verse event due to 
RBAC re ported in the in cluded clin i cal tri als (n = 11) or clin i cal case 
re ports (n = 14) [ 16 ]. Hence, the safety of RBAC with a dosage of 
3 g/ day is as sured. 
QLQ - C30 is con sid ered a re li able and valid self - reported ques tion - 
naire and is, there fore, one of the most widely used QoL ques tion - 
naires in can cer re search [ 47 ]. A sys tem atic re view that com pares 
QLQ - C30 to an other widely used can cer - specific QoL ques tion naire, 
namely Func tional As sess ment of Can cer Ther apy - General (FACT - G), 
found sub stan tial ev i dence for the re li a bil ity and va lid ity of both the 
QLQ - C30 and FACT - G in a range of can cer set tings as well as avail - 
abil ity in many lan guage trans la tions [ 48 ]. QLQ - C30 is rec om mended 
over FACT - G when so cial ac tiv i ties, fi nan cial im pact, and symp tom 
scales are out come mea sures of in ter est in a clin i cal trial [ 48 ]. How - 
ever, the global QoL scale of QLQ - C30 is less re spon sive than the 
FACT - G to tal score and thus re quires more trial par tic i pants to de tect 
changes in over all QoL [ 49 ]. With the symp tom scales be ing one of 
the pri mary out comes of in ter est in this re search, QLQ - C30 is the QoL 
in stru ment of choice. 
Mal nu tri tion in can cer is com mon, and it is a cause of di min ished 
phys i cal and men tal func tions, thus se verely low er ing the QoL 
[ 50 , 51 ]. Be ing un der weight (body mass in dex, BMI, {kg/ [height in 
m] 2 } < 18.5) is as so ci ated with re duced QoL, as sug gested in stud ies 
of var i ous can cer sur vivors, in clud ing breast [ 52 ], ovar ian [ 53 ], lung 
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[ 54 ], and col orec tal [ 55 ] can cers, as well as pa tients with metasta tic 
can cer [ 56 ]. Ad di tion ally, poor nu tri tional sta tus lead ing to weight 
loss dur ing or af ter can cer treat ment is a strong pre dic tor of poorer 
QoL [ 50 ]. As sess ment of body com po si tion is rec om mended for the 
eval u a tion of nu tri tional sta tus and de tec tion of mal nu tri tion in clin i - 
cal prac tice [ 57 ]. 
For pa tients un der go ing ac tive treat ment such as chemother apy, 
the pres ence of poor nu tri tional sta tus, anorexia, and el e vated sys - 
temic in flam ma tion also af fects QoL [ 58 ]. While lev els of pre al bu min 
and al bu min are plasma pro teins com monly used to de tect im pair - 
ment in nu tri tional sta tus, sys temic in flam ma tion can also de prive the 
pro duc tions of pre al bu min and al bu min [ 59 ]. To ac count for the ef - 
fect of sys temic in flam ma tion, the ra tio of CRP and al bu min, re ferred 
to as INI, is a suit able bio chem i cal in dex for nu tri tional as sess ment 
[ 60 ]. This study also adopts NLR as a sys temic in flam ma tory in di ca tor 
as so ci ated with the nu tri tional sta tus of can cer pa tients. Stud ies have 
shown that both INI and NLR ra tios are use ful and re li able in flam ma - 
tory and prog nos tic in di ca tors in can cer pa tients [ 60 – 63 ]. 
Pro - inflammatory cy tokines can also af fect the QoL of can cer pa - 
tients [ 64 – 66 ]. Re sults from pre clin i cal stud ies sug gest that RBAC can 
mod u late the pro duc tion of many dif fer ent cy tokines, in clud ing IL - 1β, 
IL - 6, IL - 10, IL - 17, TNF - α, and IL - 12p40 [ 10 , 67 ]. There are only a lim - 
ited num ber of hu man stud ies that val i date the cy tokine mod u lat ing 
ca pa bil ity of RBAC. An open - label RCT with 20 healthy par tic i pants 
showed that lev els of IFN - γ, TNF - α, IL - 1α, IL - 1β, IL - 6, IL - 10, and epi - 
der mal growth fac tor peaked at 30 days af ter sup ple ment ing with 
RBAC [ 68 ]. Only one RBAC clin i cal trial ex am ined the cy tokine pro - 
files of can cer pa tients. Thirty mul ti ple myeloma pa tients were ob - 
served to have in creased lev els of TNF - α, IFN - γ, IL - 5, IL - 9, IL - 12, and 
IL - 17 af ter tak ing RBAC for three months, in di cat ing in creased ac tiv - 
ity in DCs [ 69 ]. Hence, mod u la tion of cy tokine pro duc tion can be a 
po ten tial mech a nism that leads to the ef fects of RBAC on QoL of can - 
cer pa tients. 
The pre sent study will ex plore the fea si bil ity of as sess ing the im - 
munomod u lat ing ef fects of RBAC based on the quan tity and ac tiv i ties 
of the var i ous cy tokines im por tant in can cer, lever ag ing on the ad - 
dress able laser bead im munoas say (AL BIA) tech nol ogy. AL BIA is more 
ef fi cient and cost - effective than the tra di tional en zyme - linked im - 
munosor bent as say (ELISA) for test ing mul ti ple tar gets us ing small 
sam ple vol umes while of fer ing sim i lar mea sure ment ac cu racy to 
ELISA [ 70 ]. The 42 pa ra me ters, as shown in Table 4 , can be tested in 
du pli cate with only two 0.6 ml mi cro cen trifuge tubes of serum. The 
re sults of such broad - spectrum cy tokine pro file analy sis will val i date 
the find ings on the pre clin i cal stud ies and en hance the un der stand ing 
of RBAC's im munomod u lat ing prop er ties in can cer pa tients. 
Ara bi noxy lan is known to af fect hu man im mu nity as a pre bi otic 
for gut mi cro biota [ 14 ]. As a form of gly cans, ara bi noxy lan is re sis - 
tant to di ges tion by hu man en zymes. In gested ara bi noxy lans are fer - 
mented by mi cro bial en zymes in the gut to fuel the mi cro bial growth. 
The resid ual short - chain fatty acids not only serve as en ergy sources 
to tis sue cells but also have a mul ti tude of health ben e fits such as re - 
duc ing in flam ma tion, pro mot ing in testi nal ep ithe lial bar rier in tegrity, 
and sup press ing tu mor growth [ 14 ]. Com po nents of rice bran, par tic u - 
larly sol u ble fer u loy lated ara bi noxy lan oligosac cha rides (F - AXOS), 
have also been shown to mod u late the gut mi cro biome, es pe cially in 
the abun dance of Bac teroides , Pre votella , and Dorea pop u la tions [ 71 ]. 
While the phar ma co ki net ics of RBAC re mains un clear, Endo and 
Kan bayashi [ 72 ] demon strated in a pre clin i cal study that con stituents 
of RBAC could en ter the blood stream af ter oral ad min is tra tion, al beit 
the ab sorp tion was in com plete. Most pre clin i cal stud ies on RBAC have 
been fo cus ing on the di rect path way where the pres ence of RBAC in 
serum ex erts ef fects on both the in nate and adap tive im mune sys tems 
[ 13 , 16 ]. In fer ring from the re search of other ce real ara bi noxy lans and 
rice bran F - AXOS, the undi gested RBAC may po ten tially serve as pre - 
bi otics to the gut mi cro biota to fur ther mod u late the im mune sys tem. 
The pos si bil ity of this in di rect path way re mains un ex plored. To date, 
no study has at tempted to per form an analy sis us ing 16S rRNA se - 
quenc ing to un der stand the po ten tial im pact of RBAC on the al pha 
and beta di ver si ties of gut mi cro biome. The ab sence of ev i dence in 
this area rep re sents a gap in the cur rent re search which the cur rent 
study at tempts to ad dress. 
4 . Conclusion 
RBAC is one of the most well - researched low - molecular - weight 
ara bi noxy lan com pounds demon strat ing strong im munomod u lat ing 
prop er ties [ 73 ]. This study is a 24 - week ran dom ized, dou ble - blind 
placebo - controlled pi lot fea si bil ity trial on RBAC and the QoL of can - 
cer pa tients. The re sults of this study will in form the plan ning of a 
larger clin i cal trial. Such trans la tional re search will have a pos i tive 
im pact in the field of im munother apy, val i dat ing the po ten tial ap pli - 
ca tion of RBAC as a bi o log i cal re sponse mod i fier. The find ings from 
this study and fur ther re search can im prove the un der stand ing of the 
ef fect of RBAC dur ing can cer treat ment, sup ply data to val i date the 
im munother a peu tic ben e fits of RBAC, and po ten tially con tribute to 
bet ter can cer care in the fu ture. 
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